PRKAA2基因多态性与二甲双胍疗效的相关性研究

Study on correlation of genetic polymorphism of PRKAA2 with metformin response

目的研究腺苷酸活化蛋白激酶(AMP-activated pro-tein kinase,AMPK)α2亚基基因PRKAA2的单核苷酸多态性(single nucleotide polymorphism,SNP)rs2051040和rs17848595与二甲双胍疗效的关系。方法 2型糖尿病(T2DM)患者32名,服用二甲双胍干预1周(剂量为2000mg·d-1)。治疗前后分别检测空腹血糖(FPG)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)。利用聚合酶链式反应-变性梯度凝胶电泳(PCR-DGGE)技术检测PRKAA2基因rs2051040和rs17848595位点的基因型,比较不同基因型患者二甲双胍疗效的差异。结果基因型为野生型患者经过二甲双胍干预之后FPG、TG、TC、LDL-C与治疗前比较差异均有显著性(P<0.05)。基因型为突变型患者经过二甲双胍治疗之后各项生化指标变化无统计学意义(P>0.05)。结论 PRKAA2基因多态性位点rs2051040和rs17848595可以影响二甲双胍的疗效。

Aim To study the single nucleotide poly-morphism （ SNPs ） of AMP-activated protein kinase （ AMPK） α2 subunit gene PRKAA2 （ rs2051040 and rs17848595） and its relationship with metformin response. Methods A total of 32 patients with type 2 diabetes（ T2DM） were enrolled. All patients were required to take metformin for 1 week. The serum levels of FPG,TG,TC,LDL-C,HDL-C were assayed before and after therapy. The gene polymorphism of PRKAA2 was analyzed by PCR-DGGE,the effects of metformin were compared between patients with different phenotypes. Results FPG,TG,TC,LDL-C were significantly improved after therapy in wild genotype carriers（ P〈0. 05） . The biochemical indexs were not significantly different in mutant genotype carriers after therapy with metformin（ P〈0. 05） . Conclusion The results of this study suggest that PRKAA2 polymorphism may be associated with metformin treatment effects in T2DM patients.